TLR7 and cancer: In recent years, non‐invasive treatments of NMSC became available, including topical application of the TLR7 agonist imiquimod, and systemic use of immune check point inhibitors, which rely on immune cell‐mediated apoptosis of cancer cells (Love et al, 2009; Migden et al, 2018), or of hedgehog signaling inhibitors for BCC, which directly target the tumor cells (Gutzmer & Solomon, 2019).